Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Deletion of a single amino acid (K224) in the regulatory domain of the immune inhibitor factor H reveals a novel pathomechanism for membranoproliferative glomerulonephritis Type II.
-
Publication Type:Journal article
-
Publication Sub Type:Article
-
Authors:Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Beck B, Skerka C, Kirschfink M, Hoppe B, Zipfel PF
-
Publication date:2006
-
Pagination:42, 50
-
Journal:Kidney International
-
Volume:70
-
Print ISSN:0085-2538
-
Addresses:peter.zipfel@hki-jena.de
Abstract
We report a novel pathomechanism for membranoproliferative glomerulonephritis type II (MPGN II) caused by a mutant Factor H protein expressed in the plasma. Genetic analyses of two patients revealed deletion of a single Lys residue (K224) located within the complement regulatory region in domain 4 of Factor H. This deletion resulted in defective complement control: mutant protein purified from the plasma of patients showed severely reduced cofactor and decay-accelerating activity, as well as reduced binding to the central complement component C3b. However, cell-binding activity of the mutant protein was normal and comparable to wild-type Factor H. The patients are daughters of consanguineous parents. As both patients but also their healthy mother were positive for C3 nephritic factor, the mutant Factor H protein is considered relevant for unrestricted activation of the disease-causing activation of the alternative complement pathway. Replacement of functional Factor H by fresh frozen plasma (10-15 ml/kg/14 days) was well tolerated, prevented so far disease progression in both patients, and is in the long run expected to preserve kidney function.Kidney International advance online publication, 5 April 2006; doi:10.1038/sj.ki.5000269.
› More search options
UCL Researchers